# Clinical Studies for the Treatment of Advanced Solid Tumors

> **NCT06825494** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 194 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine
- **DRUG:** Tislelizumab+Oxaliplatin+Capecitabine
- **DRUG:** LM-108 injection 10mg/kg +penpulimab
- **DRUG:** LM-108 injection 600mg + penpulimab
- **DRUG:** enpulimab+ Oxaliplatin+Capecitabine

## Key facts

- **NCT ID:** NCT06825494
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-08
- **Primary completion:** 2026-03
- **Final completion:** 2026-09
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06825494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06825494, "Clinical Studies for the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06825494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*